Barraquer Eye Hospital UAE is proud to announce a groundbreaking milestone in ophthalmic care: it is the first hospital in ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the country’s medicine indicated specifically for adults with moderate to ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...

The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with moderate to severe thyroid eye disease (TED). TED is a rare autoimmune ...